The global oral controlled release drug delivery technology market is expected to grow from $34.1 billion in 2022 to $68.4 billion by 2032, with overall demand increasing at a 7.2% CAGR over the forecast period (2022 to 2032). The rising prevalence of chronic diseases, combined with a growing preference for oral drug delivery due to its numerous advantages, is the primary driver of demand for oral controlled release drug delivery technology.
The solid dosage forms segment is expected to lead the global oral controlled release drug delivery technology market with an estimated share of nearly 87% during the forecast period.
To Get the Sample Copy of Report visit@ https://www.futuremarketinsights.com/reports/sample/rep-gb-4400
Oral Solid Dosage Manufacturers in North America Enabled to Achieve Significant Bioavailability
As the preferred route of drug administration by physicians, end-user demand for oral controlled release drug delivery technology has increased in North America.
Furthermore, recent advances in drug delivery have enabled North American oral solid dosage manufacturers to achieve significant bioavailability through the use of novel drug delivery platforms.
This is expected to increase demand in the region for oral controlled release drug delivery technology.
However, rising research activities related to biologic molecules, as well as their dominance in treating oncology conditions, as well as government investments in these research activities, are expected to stifle market growth in North America.
In addition, formulation challenges such as juncture of market expectations for once-daily dosing, and growth of controlled release tablets which impart abuse resistance, incurred in oral controlled release drug delivery technology are expected to further curb growth of the market in this region.
Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-4400
New Chemical Entities Resulting from High Throughput Screening to Drive Market Growth in Western Europe
Western Europe will experience the fastest growth in the global market for oral controlled release drug delivery technology.
This expansion is primarily due to a slew of new chemical entities discovered through high throughput screening that have low solubility and bioavailability.
This has prompted manufacturers in this region to invest in drug delivery methods that produce better clinical results.
Because Western European countries are cost-conscious, technologies that improve bioavailability will continue to be the preferred drug delivery system. These factors are expected to drive market growth in this region.
However, the majority of Western European pharmaceutical companies have a complex supply chain that is either underutilised or inefficient.
The supply chain’s complexity is attributed to its lack of flexibility and cost-effectiveness. Furthermore, the shortening of effective patent life, combined with patent cliffs, is a significant challenge for oral solid dosage forms in this region.
These and other factors are expected to stifle market growth in Western Europe.
Dissolution-Controlled Release System to Remain Sought-After among Drug Release Technologies in the Market
Dissolution-controlled release systems will continue to be popular in the market, followed by diffusion-controlled release systems.
The majority of generic formulations are available in tablet form and use a dissolution-controlled release mechanism. In 2017, revenues from the sale of dissolution-controlled release systems will exceed US$ 10,000 million.
The market for hydrodynamically balanced drug delivery systems will remain sluggish.
Oral controlled release drug delivery technology in solid dosage forms is expected to remain dominant in the market, expanding at a high single-digit CAGR through 2027.
Sales of semisolid/liquid/suspensions dosage form segment will register a comparatively lower CAGR than that of solid dosage forms in the market through 2027.
Get Report Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-4400
Key market players identified in FMI’s report include
- AstraZeneca Plc.,
- Bristol-Myers Squibb Company,
- Sun Pharmaceuticals Industries Ltd,
- Abbott Laboratories,
- Merck & Co. Inc.,
- Novartis AG,
- Pfizer Inc.,
- Mylan N.V.,
- Sanofi,
- Hoffman-La-Roche Ltd.,
- Johnson & Johnson Services, Inc.,
- Vectura Group plc.,
- GlaxoSmithKline plc.
By Drug Release System
- Diffusion Controlled Release System
- Dissolution Controlled Release System
- Osmotically Controlled Release System
- Dissolution & Diffusion Controlled Release System
- Ion Exchange Resins Controlled Release
- Hydro-dynamically Balanced Drug Delivery System
- Others
By Dosage Form
- Solid Dosage Forms
- Semisolid
- Liquid/Suspension
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
